

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Angiotech Pharmaceuticals (US), Inc.		07/16/2013	CORPORATION: WASHINGTON

RECEIVING PARTY DATA

Name:	Angiotech Pharmaceuticals, Inc.
Street Address:	355 Burrard Street
Internal Address:	Suite 1100
City:	Vancouver
State/Country:	BRITISH COLUMBIA
Postal Code:	V6C 2G8
Entity Type:	CORPORATION: CANADA

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	2160032	CELLPAKER

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Email: angiotechtrademarks@angio.com

Correspondent Name: Angiotech

Address Line 1: 601 108th Ave NE

Address Line 2: Suite 1900

Address Line 4: Bellevue, WASHINGTON 98004

ATTORNEY DOCKET NUMBER:	ANPI.00001
-------------------------	------------

DOMESTIC REPRESENTATIVE

Name:

OP \$40.00 2160032

Address Line 1:
Address Line 2:
Address Line 3:
Address Line 4:

NAME OF SUBMITTER:	Nicole Hart
Signature:	/Nicole Hart/
Date:	10/29/2013

Total Attachments: 2
source=Trademark_Assignment_ANPIUS_to_ANPICA#page1.tif
source=Trademark_Assignment_ANPIUS_to_ANPICA#page2.tif

ASSIGNMENT OF TRADEMARKS

ASSIGNMENT, made effective as of June 4, 2013.

WHEREAS, Angiotech Pharmaceuticals (US), Inc., (hereinafter referred to as ASSIGNOR), a corporation organized under the laws of the state of Washington, having its principal office at 601 108th Ave NE, Suite 1900, Bellevue, Washington, 98004, USA, is the owner of rights in trademarks in the United States, which rights are acquired through use of the marks and through United States trademark registrations for such trademarks, as set forth in the SCHEDULE OF TRADEMARKS annexed hereto and made part hereof, (the trademarks, common law rights and trademark registrations hereinafter collectively referred to as the TRADEMARKS); and

WHEREAS, Angiotech Pharmaceuticals, Inc. (hereinafter referred to as ASSIGNEE), a corporation organized under the laws of Canada, having its principal office at 355 Burrard Street, Suite 1100, Vancouver, BC, Canada V6C 2G8, is desirous of acquiring all the right, title and interest of ASSIGNOR in and to the TRADEMARKS, together with the goodwill of the business associated with the TRADEMARKS; and


NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE, effective as of June 4, 2013, its successors and assigns its entire right, title and interest in and to the TRADEMARKS, together with the goodwill of the business associated with the TRADEMARKS; and

ASSIGNOR does also hereby sell, assign and transfer unto ASSIGNEE, its successors and assigns all claims for damages by reason of past infringement of the TRADEMARKS, and the right to sue for and collect the same; and

ASSIGNOR further authorizes the Commissioner of Patents and Trademarks of the United States to record the right to the TRADEMARKS as listed in the annexed SCHEDULE OF TRADEMARKS as the property of ASSIGNEE; and

ASSIGNOR further agrees to execute such further documents as may be required in the United States to record and/or establish ASSIGNEE as the owner of the TRADEMARKS, and all rights herein assigned.

July 16, 2013
Date


Name: ~~K. Thomas Bailey~~
Title: President

SCHEDULE OF TRADEMARKS

Trademark Name	Country Name	App Number	Reg Number
CELLPAKER	United States of America	75/184154	2160032
COSTASIS	Australia	775616	775616
CELLPAKER	Canada	828408	545302
COSTASIS	Canada	892735	552724
CELLPAKER	European Community	432864	432864
COSTASIS	European Community	960484	960484
CELLPAKER	Japan	H08-127834	4158975